Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-007940
Filing Date
2019-08-12
Accepted
2019-08-12 08:02:12
Documents
57
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ettx-20190630x10q.htm 10-Q 1642681
2 EX-31.1 ettx-20190630ex3113391f1.htm EX-31.1 15463
3 EX-31.2 ettx-20190630ex31241b6da.htm EX-31.2 14511
4 EX-32.1 ettx-20190630ex32189603d.htm EX-32.1 9972
  Complete submission text file 0001558370-19-007940.txt   5236690

Data Files

Seq Description Document Type Size
5 EX-101.INS ettx-20190630.xml EX-101.INS 983290
6 EX-101.SCH ettx-20190630.xsd EX-101.SCH 40845
7 EX-101.CAL ettx-20190630_cal.xml EX-101.CAL 47870
8 EX-101.DEF ettx-20190630_def.xml EX-101.DEF 150327
9 EX-101.LAB ettx-20190630_lab.xml EX-101.LAB 369338
10 EX-101.PRE ettx-20190630_pre.xml EX-101.PRE 264465
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

EIN.: 824592913 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38670 | Film No.: 191014406
SIC: 2834 Pharmaceutical Preparations